These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16054933)

  • 21. [Rimonabant (Acomplia)].
    Duh D; Vanddevijver A
    J Pharm Belg; 2008 Mar; 63(1):27-8. PubMed ID: 18479080
    [No Abstract]   [Full Text] [Related]  

  • 22. [New drugs; rimonabant].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2620-2. PubMed ID: 18161263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rimonabant for the treatment of obesity.
    Samat A; Tomlinson B; Taheri S; Thomas GN
    Recent Pat Cardiovasc Drug Discov; 2008 Nov; 3(3):187-93. PubMed ID: 18991793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Sleep disorders associated with treatment with rimonabant].
    Sempere AP; Giner-Bernabeu JC; Berenguer-Ruiz L; Selles-Galiana MF; Hernandez-Rubio L; Lezcano-Rodas M
    Rev Neurol; 2008 Oct 16-31; 47(8):446. PubMed ID: 18937208
    [No Abstract]   [Full Text] [Related]  

  • 25. [Selective cannabinoid receptor antagonists].
    Kreutz S; Korf HW; Schubert-Zsilavecz M
    Pharm Unserer Zeit; 2006; 35(6):512-20. PubMed ID: 17137082
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug development. Drugs inspired by a drug.
    Marx J
    Science; 2006 Jan; 311(5759):322-5. PubMed ID: 16424309
    [No Abstract]   [Full Text] [Related]  

  • 27. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.
    Topol EJ; Bousser MG; Fox KA; Creager MA; Despres JP; Easton JD; Hamm CW; Montalescot G; Steg PG; Pearson TA; Cohen E; Gaudin C; Job B; Murphy JH; Bhatt DL;
    Lancet; 2010 Aug; 376(9740):517-23. PubMed ID: 20709233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rimonabant and progression of atherosclerosis in obese persons.
    Dora JM; Scheffel RS
    JAMA; 2008 Jul; 300(3):280; author reply 280-1. PubMed ID: 18632538
    [No Abstract]   [Full Text] [Related]  

  • 29. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?
    Pacher P
    Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):7-9. PubMed ID: 19092136
    [No Abstract]   [Full Text] [Related]  

  • 30. [Cannabinoid receptor blocker rimonabant. CNS side effects prevent U.S. approval].
    MMW Fortschr Med; 2007 Jun; 149(27-28):8. PubMed ID: 17717874
    [No Abstract]   [Full Text] [Related]  

  • 31. Rimonabant: a rapidly expanding role in the management of metabolic and systemic disorders besides polycystic ovarian syndrome.
    Kapoor S
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):339. PubMed ID: 18625002
    [No Abstract]   [Full Text] [Related]  

  • 32. Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?
    Maccarrone M; Wang H; Dey SK
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):456-7. PubMed ID: 17302885
    [No Abstract]   [Full Text] [Related]  

  • 33. [New obesity and metabolic syndrome treatment: rimonabant].
    Makoundou V; Golay A
    Rev Med Suisse; 2006 Jan; 2(47):41-5. PubMed ID: 16465944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [2008: the end of rimonabant's story].
    Paris M
    Ann Pharm Fr; 2009 May; 67(3):167-8. PubMed ID: 19446664
    [No Abstract]   [Full Text] [Related]  

  • 35. The endocannabinoid system: potential for reducing cardiometabolic risk.
    Ginsberg HN; Woods SC
    Obesity (Silver Spring); 2009 Oct; 17(10):1821-9. PubMed ID: 19373218
    [No Abstract]   [Full Text] [Related]  

  • 36. Inhibitors of cannabinoid receptors and glucose metabolism.
    Scheen AJ; Paquot N
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):505-11. PubMed ID: 18542014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of the weight-loss drug rimonabant.
    Blüher M
    Lancet; 2008 Feb; 371(9612):555-6; author reply 556-7. PubMed ID: 18280321
    [No Abstract]   [Full Text] [Related]  

  • 38. Rimonabant in obese patients with type 2 diabetes.
    Shapiro H; Singer P
    Lancet; 2007 Feb; 369(9561):553-4; author reply 554-5. PubMed ID: 17307091
    [No Abstract]   [Full Text] [Related]  

  • 39. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna.
    Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035
    [No Abstract]   [Full Text] [Related]  

  • 40. Rimonabant in obese patients with type 2 diabetes.
    Roberfroid D
    Lancet; 2007 Feb; 369(9561):553; author reply 554-5. PubMed ID: 17307092
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.